Abstract:Objective To investigate the efficacy and safety of docetaxel chemotherapy combined with androgen-deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer.Methods One hundred and ninety-two cases of metastatic hormone-sensitive prostate cancer in Renji Hospital between January 2015 and July 2016 were analyzed retrospectively.Patients' age was 39 to 90,the median age was 71 years.The median prostate-specific antigen (PSA) at diagnosis was 90.6ng/ml (4.1-2 556.0 ng/ml).One hundred and eighty were with bone metastasis and 12 were with distant lymphatic metastasis.Sixty-one of them received docetaxel chemotherapy plus ADT for 3 weeks,131 received hormonal treatment alone.The median age of combination therapy group was 67 years (39-80 years),that of single treatment group was 75 years (50-93 years) (P ＜ 0.001).The median PSA baseline of the two groups were 91.6 ng/ml (35.5-157.5ng/ml) and 89.1 ng/ml (59.6-191.0 ng/ml) (P =0.324).Gleason score of combination therapy group showed that 3 cases (4.9％) was 6,23 cases (37.7％) 7,35 cases (57.4％) ≥8.That of single treatment group showed that 17 cases (13.0％) 6,51 cases (38.9％) 7,63 cases (48.1％) ≥8.There was no statistic difference between the two groups (P =0.122).But there was statistic difference in the rate of T3 or T4 clinical stage in primary lesion,that of combination therapy group was 50.7％ (37/61) and 34.4％ (21/61),and that of single treatment group was 60.3％ (79/131) and 21.4％ (28/131) (P =0.011).Imaging showed local lymph node metastasis in the two groups (80.3％ vs.67.9％,P =0.005).As to physical condition,the combination therapy group showed a lower ECOG score than the single treatment group (P ＜ 0.001).All the patients' survival condition,PSA response rate and adverse events were analyzed.Results One hundred and ninety-two patients were regularly followedup.The median follow-up time was 23.3 (14.4-33.4) months.Median progression free survival time of combination therapy group and single treatment group were respectively 24.4 (7.5-31.3) months vs.17.5(3.0-30.7) months (P ＜ 0.001).There were 1 and 16 cases died in the two groups due to disease progression.During the treatment,the rate of PSA level less than 0.2 ng/ml was 29.5％ (18/61) vs.13.7％ (18/131) in combination therapy group and single treatment group.Regarding the tolerance of combination therapy group,the incidence rate of grade 3-4 neutropenia was 27.9％ (17/61).Skin and mucous membrane damaged in 24.6％ (15/61) patients,transaminase rised in 13.1％ (8/61) patients,and peripheral nerve toxicity occurred in 9.8％ (6/61) patients.There was no significant difference between the 2 groups in relevant events caused by ADT,gynecomastia (14.8％ vs.16.3％) and erectile dysfunction (100％ vs.100％).Most of them could be relieved by symptomatic treatment.Conclusions For metastatic hormone-sensitive prostate cancer,docetaxel combined with hormonal treatment showed longer progression free survival than ADT alone with adverse reactions acceptable.

Combination of polypeptide AP25 and docetaxel in the treatment of breast cancer

A Meta-Analysis of Combination Therapy Versus Single-Agent Therapy in Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: Results from Nine Randomized Phase III Trials

Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference

Xiao-Ai-Ping Injection Enhances Effect of Paclitaxel to Suppress Breast Cancer Proliferation and Metastasis Via Activating Transcription Factor 3

A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines

[Randomized Clinical Case-Control Trial for the Comparison of Docetaxel Plus Thiotepa Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer].

Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro

Effects of Combination of Gefitinib and Docetaxel on Various Tumor Cell Lines in Vitro

Sensitization of Decitabine Combined with Paclitaxel on Proliferation Inhibition and Apoptosis Induction of Paclitaxel-resistant MCF-7 Cells

Combination of Baicalein and Docetaxel Additively Inhibits the Growth of Non-Small Cell Lung Cancer in Vivo

Effect of the combined use of docetaxel, cisplatin and apatinib mesylate on serum tumor markers and prognosis in advanced ovarian cancer patients

Study on anti-tumor effects of polypeptide AP25

Docetaxel Chemotherapy Combined with Androgen-Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: an Efficacy and Safety Analysis

Efficacy and Prognosis of First-Line Chemotherapy with Docetaxel Monotherapy or Docetaxel in Combination with Thiotepa in Treatment of Metastatic Breast Cancer

Combination of Gemcitabine Antagonizes Antitumor Activity of Paclitaxel Through Prevention of Mitotic Arrest and Apoptosis

[Phase II Study of Docetaxel Plus Epirubicin Versus Docetaxel Plus Cisplatin As First-Line Chemotherapy for Advanced Breast Cancer].

Potentiation of paclitaxel activity by curcumin in human breast cancer cell by modulating apoptosis and inhibiting EGFR signaling

A Dual Bispecific Hydrolysis Peptide-Drug Conjugate Responsive to Micro-Acidic and Reduction Circumstance Promotes Antitumor Efficacy in Triple-Negative Breast Cancer

Short-term Curative Effects of Docetaxel Combined with Capecitabine in Neoadjuvant Chemotherapy of Triple-negative Breast Cancer and Non Triple-negative Brest Cancer

Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells

Comparison Between Doublet Agents Versus Single Agent in Metastatic Breast Cancer Patients Previously Treated with an Anthracycline and a Taxane: a Meta-Analysis of Four Phase III Trials.